Loading…
Research conducted on mice has indicated that the gut microbiota may play a role in contributing to obesity. This occurs through the anorexigenic gut hormone known as glucagon-like peptide 1 (GLP1) and bile acids, both of which have an impact on lipid metabolism (1).
NCT02741518 - Fecal Microbiota Transplantation (FMT) & Adiposity / Obesity is a randomized clinical phase I/II treatment trial studying Fecal Microbiota Transplantation (FMT) or placebo in patients with Adiposity / Obesity (BMI of 35kg/m^2 or higher)
Adverse Event Frequency
Adverse Events: There were no significant differences in adverse events between patients who received Fecal Microbiota Transplantation (FMT) and those who received a placebo.
GLP1 Levels: The area under the curve of GLP1 did not increase in either group.
Microbiome Shifts: Patients who received FMT experienced sustained shifts in their microbiomes, moving from profiles associated with obesity toward those of the donor, with a statistically significant change (P < .001).
Bile Acid Profiles: There was a sustained decrease in stool levels of taurocholic acid in the FMT group compared to baseline (P < .05). The bile acid profiles of these patients began to more closely resemble those of the donor.
BMI Changes: No significant changes in mean Body Mass Index (BMI) were observed at week 12 in either group (1)
In our study, we discovered that FMT capsules, which are derived from a lean donor, were safe for use. However, they did not result in a reduction of BMI in patients who are obese but metabolically uncompromised. The capsules were well tolerated by the patients and brought about lasting changes in the intestinal microbiome and bile acid profiles, aligning them closely with those of the lean donor (1).
(1)